Literature DB >> 35949621

Role of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio and platelets in prognosis of patients with prostate cancer.

Joanna Huszno1,2, Zofia Kołosza3, Jolanta Mrochem-Kwarciak4, Ewa Telka1, Bożena Jochymek1, Leszek Miszczyk1.   

Abstract

The aim of the present analysis was to evaluate the platelet-lymphocyte ratio (PLR), neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelets (PLT) and neutrophil level for their prognostic values in patients with prostate cancer who had been treated with radiotherapy. A retrospective analysis of 152 patients who were treated in the Radiotherapy Department at Maria Sklodowska-Curie National Research Institute of Oncology (Gliwice, Poland) between January 2012 and December 2014 was performed. The prognostic value (overall survival; OS) of the pre-treatment PLR, NLR, LMR, PLT, neutrophil level and other laboratory factors such as: leukocyte, lymphocyte, monocyte, hemoglobin, RBC, prostate-specific antigen level (PSA), Gleason score, age, smoking and comorbid condition were assessed using univariate analysis. The cut-off point was determined for NLR as 'elevated' at >4.66, LMR >3.26 and the PLR was considered 'elevated' at >89.6. Median follow-up was 4.9 years. The 5 and 7-year OS rates were 81.5 and 72.2%, respectively. In univariate analysis higher NLR (P=0.007), higher level of PLT (P=0.004), higher level of neutrophils (P=0.013), elevated level of leukocyte (P=0.043) and lymphocyte (P=0.043) were factors significantly associated with decreased OS. No difference was found for PLR (P=0.308) and LMR (P=0.109). The other factor associated with decreased OS were: higher Gleason score (>7; P=0.005), higher PSA level (>20 ng/dl; P=0.0001), smoking (P=0.003) and older age (>70 years; P=0.018). In multivariate analysis, NLR, LMR, leukocyte and RBC were independently associated with prognosis in patients with prostate cancer. Elevated pre-treatment NLR [hazard ratio (HR)=10.83; P=0.001), LMR (HR=3.14; P=0.007) and higher leukocyte level (HR=3.14; P=0.007) were independently associated with increased mortality risk. Overall, pre-treatment NLR, PLR, leukocyte and RBC levels were revealed to be independent prognostic factors.
Copyright © 2022, Spandidos Publications.

Entities:  

Keywords:  lymphocyte-monocyte ratio; neutrophil-lymphocyte ratio; platelet-lymphocyte ratio; platelets; prognostic factors; prostate cancer; radiotherapy

Year:  2022        PMID: 35949621      PMCID: PMC9353225          DOI: 10.3892/ol.2022.13425

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   3.111


  12 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  Platelets, inflammation and tissue regeneration.

Authors:  Alan T Nurden
Journal:  Thromb Haemost       Date:  2011-04-11       Impact factor: 5.249

3.  Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl.

Authors:  Volkan Caglayan; Efe Onen; Sinan Avci; Murat Sambel; Metin Kilic; Sedat Oner; Mustafa Murat Aydos; Halil Emre Yıldız
Journal:  Arch Ital Urol Androl       Date:  2019-01-17

Review 4.  Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review.

Authors:  Alessandro Sciarra; Alessandro Gentilucci; Stefano Salciccia; Federico Pierella; Flavio Del Bianco; Vincenzo Gentile; Ida Silvestri; Susanna Cattarino
Journal:  J Inflamm (Lond)       Date:  2016-11-25       Impact factor: 4.981

Review 5.  Epidemiology of Prostate Cancer.

Authors:  Prashanth Rawla
Journal:  World J Oncol       Date:  2019-04-20

6.  Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis.

Authors:  Hao Peng; Xiaogang Luo
Journal:  Cancer Cell Int       Date:  2019-03-25       Impact factor: 5.722

7.  Development and validation of a nomogram including lymphocyte-to-monocyte ratio for initial prostate biopsy: a double-center retrospective study.

Authors:  Zhong-Han Zhou; Feng Liu; Wen-Jie Wang; Xue Liu; Li-Jiang Sun; Yao Zhu; Ding-Wei Ye; Gui-Ming Zhang
Journal:  Asian J Androl       Date:  2021 Jan-Feb       Impact factor: 3.285

8.  Prognostic role of pretreatment platelet to lymphocyte ratio in urologic cancer.

Authors:  Jianfeng Wang; Yang Liu; Naiwen Zhang; Xuejie Li; Peng Xin; Jianbin Bi; Chuize Kong
Journal:  Oncotarget       Date:  2017-08-10

Review 9.  Prognostic role of platelet to lymphocyte ratio in prostate cancer: A meta-analysis.

Authors:  Jiangfeng Wang; Xiaofeng Zhou; Yuhui He; Xing Chen; Naibo Liu; Zhenshan Ding; Junjie Li
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

Review 10.  Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Xiaotao Yin; Yi Xiao; Fanglong Li; Siyong Qi; Zhaoyang Yin; Jiangping Gao
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.